KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medpace Holdings (MEDP) EBITDA Margin (2016 - 2025)

Medpace Holdings' EBITDA Margin history spans 11 years, with the latest figure at 22.61% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 209.0% year-over-year to 22.61%; the TTM value through Dec 2025 reached 22.22%, down 29.0%, while the annual FY2025 figure was 22.22%, 29.0% down from the prior year.
  • EBITDA Margin reached 22.61% in Q4 2025 per MEDP's latest filing, roughly flat from 22.52% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 24.7% in Q4 2024 to a low of 16.67% in Q2 2021.
  • Average EBITDA Margin over 5 years is 20.6%, with a median of 20.9% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: plummeted -342bps in 2021, then soared 589bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 19.13% in 2021, then increased by 8bps to 20.68% in 2022, then dropped by -9bps to 18.8% in 2023, then surged by 31bps to 24.7% in 2024, then fell by -8bps to 22.61% in 2025.
  • Per Business Quant, the three most recent readings for MEDP's EBITDA Margin are 22.61% (Q4 2025), 22.52% (Q3 2025), and 22.06% (Q2 2025).